Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eltrombopag with induction chemotherapy in acute myeloid leukemia
2013-000642-20Phase 2Completed
- Sponsor
- GSK
- Start
- Jun 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acute myeloid leukemia (AML) comparing Eltrombopag + standard induction therapy with Placebo + standard induction therapy (2 arms). Primary endpoint: Safety and tolerability. Started Jun 2013; status: completed.
02
Drugs
eltrombopag
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2013-000642-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000642-20.